BioSpace News Archive

Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced details for the release of its results for the third quarter ended September 30, 2021.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), today announced that it has received approval from Health Canada to begin a Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases.

OpenEye Scientific, an industry leader in computational molecular design, has officially introduced its Scientific Advisory Board, which includes experts in the fields of biophysics and molecular modeling.

MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophageal space, has added Ty Miller to the management team as National Sales Director.

GenesisCare — one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom — today announced it will be expanding access to the novel fluorinated prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging capabilities in its Florida, South Carolina, and Texas centers.

- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2021, after the market close on November 4, 2021.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries announces their successful up-listing to OTCQB trading status, effective as of the open of trading on October 28, 2021.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) today announced its EsoGuard® Esophageal DNA Test has been selected as winner of the “Diagnostics Innovation of the Year” award in the inaugural awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.